$GILD Headlines Don’t look for pricey hepatitis drugs

New Post Public Reply Private Reply Replies (0) Message Board

Jan 17, 2015 at 9:50 AM

$GILD Headlines

Don’t look for pricey hepatitis drugs to come down 2:32 p.m. Jan. 13, 2015 - Russ Britt
Three investments to own and three to 6:00 a.m. Jan. 13, 2015 - Howard Gold
Wynn, Newmont lead gainers; Macy’s, Bed Bath & Beyond slump 11:05 a.m. Jan. 9, 2015 - Sue Chang
Fifteen stocks for 2015, part 1 10:36 a.m. Jan. 9, 2015 - The Trading Deck
AbbVie predicts sharp increase in earnings 4:56 p.m. Jan. 8, 2015 - MarketWatch.com
Gilead Sciences shares rise 2.4% 9:32 a.m. Jan. 6, 2015 - Sue Chang
Gilead to buy liver disease treatment from Germany's Phenex 8:39 a.m. Jan. 6, 2015 - Ciara Linnane
Gilead, CVS strike deal on Hepatitis C drugs 1:47 p.m. Jan. 5, 2015 - Russ Britt
Eight charts plot the year in finance 12:45 p.m. Dec. 30, 2014 - Ophir Gottlieb
Are consumers getting gouged on health care? 9:35 a.m. Dec. 30, 2014 - Russ Britt
S&P 500 rises to record, but Dow snaps 7-day win streak 4:24 p.m. Dec. 29, 2014 - Sara Sjolin
Manitowoc, Gilead climb; Tesla slips 11:12 a.m. Dec. 29, 2014 - Wallace Witkowski
Mon., Dec. 29, 2014: Watch Manitowoc Stock 10:32 a.m. Dec. 29, 2014 - MarketWatch
Gilead shares up 3% as Morgan Stanley upgrades to overweight 10:07 a.m. Dec. 29, 2014 - Ciara Linnane
Gilead shares up 2.9% in early trade 9:52 a.m. Dec. 29, 2014 - Ciara Linnane
Gilead upgraded to overweight from equal-weight at Morgan Stanley 9:52 a.m. Dec. 29, 2014 - Ciara Linnane
U.S. Stock Futures Fall, Following Europe's Lead 9:51 a.m. Dec. 29, 2014 - MarketWatch
Gilead Sciences, energy plays lead S&P advancers 9:34 a.m. Dec. 29, 2014 - Silvia Ascarelli
Why speculators see opportunity in younger, cyclical stocks 2:50 p.m. Dec. 26, 2014 - The Trading Deck
GoPro, Gilead Sciences, Celgene gain 11:27 a.m. Dec. 26, 2014 - MarketWatch

United Therapeutics Clears Hypertension Drug Hurdles 5:44 p.m. Jan. 16, 2015 - Investors Business Daily
Seeking Alpha's Biotech Weekly: Roche Takes Control, Shire's A Buyer, And More 4:00 p.m. Jan. 16, 2015 - Seeking Alpha
Aetna Sides With Gilead In Hepatitis C Drug Battle 2:43 p.m. Jan. 16, 2015 - Investors Business Daily
Gilead: A Bullish Update 2:08 p.m. Jan. 16, 2015 - Seeking Alpha
How To Play Gilead In 2015: It's Going To Be A Bumpy Ride 1:45 p.m. Jan. 16, 2015 - Seeking Alpha
5 Stock Picks For 2015 10:18 a.m. Jan. 16, 2015 - Seeking Alpha
Nomura's Takeaways From Meeting With Gilead Sciences' Management 9:17 a.m. Jan. 16, 2015 - benzinga.com
3 Best Mutual Funds for Healthcare Stocks 8:15 a.m. Jan. 16, 2015 - InvestorPlace.com
Gilead Sciences' Recent Trading Pattern Is Much To Do About Nothing 8:13 a.m. Jan. 16, 2015 - Seeking Alpha
AbbVie HCV treatment cleared in Europe 7:58 a.m. Jan. 16, 2015 - Seeking Alpha
Veteran Analyst’s Top Health-Care Picks for 2015 11:38 a.m. Jan. 15, 2015 - Barrons.com
Eli Lilly Has 'Turned The Corner,' Upgraded 10:02 a.m. Jan. 15, 2015 - Investors Business Daily
Amgen Will Deliver In 2015 8:22 a.m. Jan. 15, 2015 - Seeking Alpha
India patent office slaps Gilead in the face 3:25 p.m. Jan. 14, 2015 - Seeking Alpha
What To Do When A Bear Market Is Imminent 3:09 p.m. Jan. 14, 2015 - Seeking Alpha
Gilead Sciences' Sovaldi Patent Application Rejected In India 12:08 p.m. Jan. 14, 2015 - benzinga.com
Regado Bio and Tobira to merge 9:42 a.m. Jan. 14, 2015 - Seeking Alpha
Express Scripts is Biotech's Grinch 9:13 a.m. Jan. 14, 2015 - Seeking Alpha
Express Scripts Eyes New Price War: Anti-PCSK9 Drugs 6:06 p.m. Jan. 13, 2015 - Investors Business Daily
AbbVie Inc.'s Forthcoming Future Looks Optimistic 1:55 p.m. Jan. 13, 2015 - GuruFocus.com

Earnings Forecast Research for Apple, Bank of America, Freeport-McMoRan, Agenus, Alibaba, and Sirius XM 8:45 a.m. Jan. 14, 2015 - PR Newswire - PRF
Gilead Sciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13 5:00 p.m. Jan. 12, 2015 - BusinessWire - BZX
Reveal Earnings Forecast for Arena Pharmaceuticals, Petrobras, Alibaba, Apple, Gilead Sciences, and Applied Materials 8:45 a.m. Jan. 9, 2015 - PR Newswire - PRF
Earnings Forecast for Apple, Alibaba, Twitter, Gilead Sciences, Michael Kors, and Tesla 8:45 a.m. Jan. 7, 2015 - PR Newswire - PRF
Biotechs to Follow in 2015 off Fresh Insider Moves 10:00 a.m. Jan. 6, 2015 - ACCESSWIRE
Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals’ Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases 8:31 a.m. Jan. 6, 2015 - BusinessWire - BZX
Factors Moving Markets: Complementary Reports on United Parcel Service, Gilead, Manitowoc, EMC Corporation, and LiveDeal 9:10 a.m. Dec. 30, 2014 - PR Newswire - PRF
Biotech Stocks Technical Data -- Gilead Sciences, ImmunoGen, Exelixis, Cubist Pharma, and Vanda Pharma 8:55 a.m. Dec. 30, 2014 - PR Newswire - PRF
Gilead Announces Amended Agreements With Janssen to Develop and Commercialize Tenofovir Alafenamide-Based Single Tablet Regimens for HIV Treatment 8:30 a.m. Dec. 29, 2014 - BusinessWire - BZX
Critical Alerts For Achillion Pharmaceuticals, AT&T, Peabody Energy, Gilead Sciences and Facebook Released By InvestorsObserver 9:31 a.m. Dec. 23, 2014 - PR Newswire - PRF
AHF Lauds Express Scripts for Dropping Gilead’s Sovaldi in Favor of Cheaper Hepatitis C Treatment 9:01 a.m. Dec. 23, 2014 - BusinessWire - BZX
Pharmaceuticals, Medicines, Supplements and Drug Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 325400 8:15 a.m. Dec. 23, 2014 - PR Newswire - PRF
Reveal Earnings Forecast for Apple, Halliburton, American Realty Capital Properties, Gilead Sciences, Zynga, and Bank of America 8:45 a.m. Dec. 16, 2014 - PR Newswire - PRF
Philippe C. Bishop, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutics 8:30 a.m. Dec. 15, 2014 - BusinessWire - BZX
Critical Alerts For Abercrombie & Fitch, Whole Foods Market, Gilead Sciences, JC Penney and Activision Blizzard Released By InvestorsObserver 9:31 a.m. Dec. 10, 2014 - PR Newswire - PRF
Class Action Lawsuit Challenges the Exorbitant Pricing of Gilead's Hepatitis-C Drug Sovaldi 6:39 p.m. Dec. 9, 2014 - PR Newswire - PRF
BetterInvesting Magazine Releases February Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use 4:43 p.m. Dec. 9, 2014 - PR Newswire - PRF
Biogen Idec and Gilead Sciences Join the National Pharmaceutical Council 9:15 a.m. Dec. 9, 2014 - PR Newswire - PRF
Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma 10:00 a.m. Dec. 8, 2014 - BusinessWire - BZX
Reveal Earnings Forecast for Gilead Sciences, Apple, Transocean, Halliburton, Ctrip, and Sirius XM 8:45 a.m. Dec. 8, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cracking the Code of America's Delivery Addiction

America's New Obsession: Convenience at a Cost Diving into the relentless hustle, Americans are shelling out big bucks to dodge life's mundane chores. A fresh survey dished out by FinanceBuzz, hitching a ride with Bank of America, gives us a peek into how hooked everyone is on convenience services like food and grocery deliveries. It’s clear people are ready to fork...

Davos Healthcare Aims to Revolutionize Hospital Ratings

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Compass Unveiled: Power Revolution in Private Equity

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Succession Planning in Turmoil: Only 42% Ready

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

The Chemical Industry and EPA: A Broken System?

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Anecdotes by Artists Brings Raw Scent Stories to Sephora

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

FJBio Boosts Antibody Discovery with Sapio AI

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Leapora's Taskeen: Redefining Task Accountability

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

HTX's Strategic Moves in Pakistan: A Crypto Frontier

Paving the Way: HTX's Journey in Pakistan Rolling into the Pakistan cryptocurrency scene isn't just a 'walk in the park' for HTX—it's more like traversing a new frontier with an open map. This isn’t some hit-and-run operation; HTX is strategizing for a long haul in one of the liveliest digital market arenas in South Asia. Gathering steam with community AMAs and an X...

Machine Grabs Prime Dallas Property Amid Apartment Boom

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...